Longboard Pharmaceuticals Appoints Brandi L. Roberts as Chief Financial Officer
January 21 2021 - 8:30AM
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical
company focused on developing novel, transformative medicines for
neurological diseases, today announced the appointment of Brandi L.
Roberts as its Chief Financial Officer.
"Brandi’s strong financial acumen and experience
within the life sciences sector will be key as we position the
company for long-term growth and advance our assets in a range of
neurological diseases," stated Kevin R. Lind, Longboard’s President
and Chief Executive Officer. "I am pleased to welcome Brandi to the
team."
Previously, Ms. Roberts served as Chief
Financial Officer of Lineage Cell Therapeutics, Inc. (LCTX) from
January 2019 to January 2021. Prior to joining Lineage in January
2019, she served as Chief Financial Officer of REVA Medical, Inc.
since August 2017. Ms. Roberts previously served as Chief Financial
Officer of Mast Therapeutics, Inc. from January 2013 to April 2017,
and as its Senior Vice President, Finance, from March 2011 to
January 2013. Previously, she held senior positions at Alphatec
Spine, Inc., Artes Medical, Inc., Stratagene Corporation, and
Pfizer, Inc. Ms. Roberts currently serves as Chair of the Southern
California Chapter of the Association of Bioscience Financial
Officers and has served on the Board of Temple Therapeutics BV
since November 2019. Ms. Roberts brings more than 25 years of
public accounting and finance experience, including 22 years at
publicly traded pharmaceutical, medical technology, and life
science companies to her position. Ms. Roberts is a certified
public accountant with the State of California and received her
B.S. degree in business administration from the University of
Arizona and her M.B.A. from the University of San Diego.
About Longboard
PharmaceuticalsLongboard Pharmaceuticals, Inc. (Longboard)
is a clinical-stage biopharmaceutical company focused on developing
novel, transformative medicines for neurological diseases.
Longboard was formed in January 2020 by Arena Pharmaceuticals, Inc.
(Arena) to advance a portfolio of centrally acting product
candidates designed to be highly selective for specific G
protein-coupled receptors (GPCRs). Longboard’s small molecule
product candidates were discovered out of the same platform at
Arena that represents a culmination of more than 20 years of GPCR
research. Longboard is evaluating LP352, an oral, centrally acting,
5-hydroxytryptamine 2c receptor subtype superagonist, in
development for the potential treatment of developmental and
epileptic encephalopathies. Longboard is also evaluating LP143, a
centrally acting, full cannabinoid type 2 receptor agonist, in
development for the potential treatment of neurodegenerative
diseases associated with neuroinflammation caused by microglial
activation, and LP659, a centrally acting, sphingosine-1-phosphate
receptor subtypes 1 and 5 modulator, in development for the
potential treatment of central nervous system neuroinflammatory
diseases.
Corporate Contact:Megan E. KnightHead of
Investor
Relations mknight@longboardpharma.comIR@longboardpharma.com619.592.9775
Longboard Pharmaceuticals (NASDAQ:LBPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Longboard Pharmaceuticals (NASDAQ:LBPH)
Historical Stock Chart
From Jul 2023 to Jul 2024